-
Product Insights
NewHospital Acquired Pneumonia (HAP) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Hospital Acquired Pneumonia (HAP) Clinical Trial Report Overview A total of 581 HAP clinical trials were conducted as of April 2024. The HAP clinical trial report provides a comprehensive understanding of the HAP clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·      North America ·      Europe...
-
Sector Analysis
NewAmyotrophic Lateral Sclerosis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2029
This report covers the 8MM (US, France, Germany, Italy, Spain, UK, Japan and Canada) and provides an Excel-based forecast model for the Amyotrophic Lateral Sclerosis (ALS) market through 2029. The prevalence of ALS is increasing at a steady rate, in line with population growth in the 8MM, at an annual growth rate (AGR) of 0.79%.The diagnosed prevalent cases of ALS across the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Canada) are expected to increase from...
-
Product Insights
NewJuvenile Macular Degeneration (Stargardt Disease) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Juvenile Macular Degeneration Clinical Trial Report Overview A total of 59 Juvenile Macular Degeneration clinical trials were conducted as of April 2024. The Juvenile Macular Degeneration clinical trial report provides a comprehensive understanding of the Juvenile Macular Degeneration clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions...
-
Sector Analysis
NewPost-Operative Pain (POP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Post-Operative Pain (POP) Marketed and Pipeline Drugs Report Overview Post-operative pain (POP) is considered a form of acute pain due to surgical trauma with an inflammatory reaction and initiation of an afferent neuronal barrage. There could also be some generalized body pain before the operation with aggravation after the operation. This type of operation often needs complete or partial anesthesia. Disturbances in the channels and collaterals or the internal organs may be the cause. Key Mechanisms of Action (Marketed) ·      ...
-
Sector Analysis
NewAttention Deficit Hyperactivity Disorder (ADHD) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Attention Deficit Hyperactivity Disorder (ADHD) market through 2032. The prevalent cases of ADHD in the 7MM will increase from 21,141,036 to 21,970,997, at an annual growth rate (AGR) of 0.4% over the forecast period. The ADHD market was valued at $11.9 billion in the 2022 baseline year. Over the 10-year forecast period, the market is projected to decline at a...
-
Product Insights
Bronchiectasis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Bronchiectasis Clinical Trial Report Overview A total of 394 Bronchiectasis clinical trials were conducted as of March 2024. The Bronchiectasis clinical trial report provides a comprehensive understanding of the Bronchiectasis clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·       Asia-Pacific ·       Europe ·       North America ·       ...
-
Sector Analysis
NewResistant Hypertension (RH) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Resistant Hypertension (RH) Marketed and Pipeline Drugs Report Overview Resistant Hypertension (RH) refers to high blood pressure (BP) that is above the target level in a patient. This occurs even when they are taking three different classes of antihypertensive medications concurrently. These medication classes typically include diuretics, long-acting calcium channel blockers, and renin-angiotensin system blockers (ACEs or ARBs). The Resistant Hypertension (RH) marketed, and pipeline drugs research report includes an assessment of the disease epidemiology, leading marketed products with sales...